Island
Eye is recognized as a leader in the field of surgical eye care. Many of
Long Island's premier Ophthalmic Surgeons have chosen Island Eye as the
facility that they prefer when performing complicated ophthalmic surgery.
In
January 2004, Island Eye completed a major building renovation to better
serve our patients and visitors' needs while at the center.
Island
Eye has become an approved clinical site for many advanced research
studies on new drugs and medical devices. This is true testimony to the
quality of care offered here. The site selection and approval process is
very rigorous, and we are proud of our contributions to the scientific
process that will ultimately enhance the visual potential of patients
worldwide.
AMO
Tecnis Lens
Island
Eye was one of the first centers on Long Island to offer its patients
the new AMO (Advanced Medical Optics) Tecnis Lens. This lens has been
discussed extensively in the media for its benefit to cataract surgery patients. The Tecnis lens is the only cataract surgery lens approved by
the FDA to minimize the potential for having an auto accident at night
in low light conditions. This lens improves "functional
vision" as well as emergency reaction time. To learn more about the
Tecnis lens, you can visit www.tecnisiol.com
or ask you eye doctor.
Tecnis
Multifocal Lens
Island
Eye has also been chosen as a site for the clinical trial of the new
Tecnis Multifocal Lens. This new Tecnis lens will not only improve
vision in low light conditions, but give true multifocal vision.
Patients who receive this lens will have the ability to benefit from
improved distance as well as reading vision. Current cataract implant
lens technology primarily addresses improvements in distance vision, and
patients often still require reading glasses. This is very exciting new
technology and Island Eye is proud to participate in the research.
Veriseyes
Phakic IOL
Another
recent advance in lens technology is the Veriseyes Phakic IOL. This
implantable lens, also manufactured by AMO, and featured in Newsday and
the New York Times, corrects vision in patients who are not candidates
for traditional LASIK surgery. Island Eye participated in the
initial clinical research that assisted AMO in getting this lens
approved by FDA. One of our surgeons, Dr. Eric Donnenfeld, was a medical
monitor and the first surgeon to use this lens on Long Island.
Island Eye continues in its role as a clinical training site for
surgeons wishing to learn how to use this lens.
